Crinetics
NASDAQ: CRNXSan Diego, US · Founded 2008 · 641 employees on LinkedIn · 5 known investors
Find your way into Crinetics
185 people in our graph share verified history with the Crinetics team — schools, employers, funds. One of them is your warm intro.
Eric Wagnerunlockedknows Stephen F. Betz · together at The University of North Carolina at Chapel Hill (overlapped)
knows the team · via The University of North Carolina at Chapel Hill
knows the team · via Radionetics
×9knows the team · via University of Delaware
Crinetics is a pharmaceutical company focused on discovering, developing, and commercializing therapies for endocrine diseases and endocrine-related conditions.
Founders & leadership
Crinetics was founded in 2008 by Richard Scott Struthers, Stephen F. Betz, and Stephen Betz.
RS
Richard Scott StruthersCo-founder
SF
Stephen F. BetzinCo-founder · Chief Scientific OfficerStephen F. Betz is an Executive Officer at Crinetics Pharmaceuticals, a company focused on drug discovery and pharmaceutical development. He has worked in drug discovery, preclinical development, molecular pharmacology, and receptor biology across pharmaceutical and biotechnology organizations.
SB
Stephen BetzinCo-founder · Chief Scientific OfficerStephen Betz is Chief Scientific Officer of Crinetics, a pharmaceutical company developing therapies for endocrine diseases. He has experience in drug discovery, preclinical development, lead optimization, molecular pharmacology, and assay development across pharmaceutical and biotechnology companies.
RS
R. Scott StruthersinFounder, CEO2008–2026R. Scott Struthers is President, Chief Executive Officer and Director of Crinetics, a pharmaceutical company developing therapies for endocrine diseases and related conditions. He has expertise in drug discovery, development, and biotech talent management across research areas including neuroendocrinology, structural pharmacology, and endocrinology.
TS
Tobin SchilkeinChief Financial OfficerTobin Schilke is Chief Financial Officer of Crinetics, a pharmaceutical company developing therapies for endocrine diseases. He has over 25 years of biopharma industry experience in finance, IT, and operations, with a track record of raising capital and executing M&A transactions.
IK
Isabel KalofonosinChief Commercial Officer (CCO)Isabel Kalofonos holds the role of Chief Commercial Officer at Crinetics, a pharmaceutical company developing therapies for endocrine diseases. She has held positions at Shire and Takeda, where she worked on product commercialization, market access, and pricing strategy.
YZ
YunFei ZhuNamed on SEC filing
Board
MS
SK
Steve KaldorBoard director
MF
WW
Wendell WierengaBoard director
Investors · 5
Reported raises · per SEC filings
Form D private placements$428M disclosed across 3 rounds · 2015–2024
▶$350MraisedMar 2024 · 36 investors · BiotechnologyRule 506(b)
▶$350MraisedMar 2024 · 36 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- JAMES HASSARDExecutive Officer
- STEPHEN BETZExecutive Officer
- ROGERIO VIVALDI COELHO, M.D.Director
- WESTON NICHOLS, PhDDirector
- MARC WILSONExecutive Officer
- CAMILLE BEDROSIAN, M.D.Director
- MATTHEW FUSTDirector
- RICHARD SCOTT STRUTHERS, PhDExecutive Officer, Director
- JEFF KNIGHTExecutive Officer
- WENDELL WIERENGA, PhDDirector
- DANA PIZZUTIExecutive Officer
- CAREN DEARDORFDirector
- STEPHANIE OKEYDirector
- Offering amount
- $350M
- Amount sold
- $350M
- Sales commissions
- $14M
- Placement agents
- LIFESCI CAPITAL, LLC, H.C. WAINWRIGHT & CO., LLC, ROBERT W. BAIRD & CO. INCORPORATED, PIPER SANDLER & CO., LEERINK PARTNERS LLC, CITIZENS JMP SECURITIES, LLC
- First sale
- Mar 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$60MraisedFeb 2018 · 12 investors · PharmaceuticalsRule 506(b)
▶$60MraisedFeb 2018 · 12 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Mason Freeman, M.D.Director
- Matthew K. FustDirector
- Wendell Wierenga, Ph.DDirector
- Richard Scott Struthers, Ph.DExecutive Officer, Director
- Steve Kaldor, Ph.DDirector
- Marc WilsonExecutive Officer
- Weston Nichols, Ph.DDirector
- Jack B. NielsenDirector
- Offering amount
- $65M
- Amount sold
- $60M
- First sale
- Feb 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$18MraisedNov 2015 · 8 investors · PharmaceuticalsRule 506(b)
▶$18MraisedNov 2015 · 8 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- YunFei ZhuExecutive Officer
- Steve KaldorDirector
- Mason FreemanDirector
- Wendell WierengaDirector
- Richard Scott StruthersExecutive Officer, Director
- Mahendra ShahDirector
- Stephen F. BetzExecutive Officer
- Offering amount
- $40M
- Amount sold
- $18M
- Proceeds to insiders
- $41.4K
- First sale
- Oct 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 11 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2018 | $1.9M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2017 | $2.8M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2017 | $299.5K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2017 | $297.4K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2015 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2015 | $326.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2014 | $224.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2013 | $2.2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2012 | $296.3K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2011 | $282.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2010 | $237.9K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Crinetics do?
- Crinetics is a pharmaceutical company focused on discovering, developing, and commercializing therapies for endocrine diseases and endocrine-related conditions.
- Who founded Crinetics?
- Crinetics was founded by Richard Scott Struthers, Stephen F. Betz, Stephen Betz in 2008.
- Who are Crinetics's investors?
- Crinetics's investors include 5AM Ventures, Foresite Capital, OrbiMed, RA Capital, Vivo Capital.
- How much funding has Crinetics raised?
- Crinetics has disclosed $428M raised across 3 rounds.
- Where is Crinetics headquartered?
- Crinetics is headquartered in San Diego, US.